A 28-day placebo-controlled pilot study by Cipran- di et al73 compared fexofenadine 120 and 180 mg with placebo in 31 subjects (52% male, 48% female; mean age, 27 years [range, 18–80 years]) with a ≥2-year his- tory of moderate to severe PAR. By day 7 of treat- ment, subject- and investigator-rated nasal congestion was significantly reduced compared with placebo with both fexofenadine 120 mg (P = 0.027) and fexofena- dine 180 mg (P = 0.01). Fexofenadine 120 and 180 mg also were associated with significant reductions in na- sal congestion scores at the final visit (P = 0.011 and P = 0.007, respectively).